Table 2.
Immunization scheme of patients separated according to diagnosis. ID intradermal immunization, IN ultrasound-guided intranodal immunization, SD stable disease, PD progressive disease, OR objective response
| Patient number | Tumor cells/dose (×10−7) | Doses received | Immunization route | Response (at 3 months) | Duration of response (months)a |
|---|---|---|---|---|---|
| Renal cell carcinoma | |||||
| 1 | 1.0 | 5 | ID | SD | 8 |
| 2 | 0.6 | 4 | ID (2) IN (2) | SD | 19+ |
| 4 | 0.6 | 3 | ID | SD | 19+ |
| 5 | 3.0 | 4 | IN | SD | 4 |
| 6 | 0.6 | 8 | ID (6) IN (2) | OR | 21 |
| 8 | 0.6 | 5 | IN | SD | 15+ |
| 9 | 0.6 | 5 | ID | SD | 6 |
| 10 | 1.9 | 8 | ID (1) IN (7) | SD | 18+ |
| 11 | 0.6 | 4 | ID (3) IN (1) | SD | 6 |
| 12 | 2.0 | 2 | IN | SD | 12 |
| 13 | 0.6 | 4 | ID | OR | 5 |
| 15 | 0.6 | 3 | IN | PD | – |
| 16 | 0.6 | 2 | IN | PD | – |
| 17 | 1.5 | 3 | IN | SD | 4 |
| 18 | 0.6 | 3 | IN | SD | 12+ |
| 19 | 1.0 | 3 | ID | SD | 4 |
| 20 | 1.0 | 3 | ID | SD | 4 |
| 21 | 2.0 | 6 | ID (1) IN (5) | OR | 7 |
| 22 | 0.8 | 5 | IN | SD | 6+ |
| 14b | 1.0 | 1 | ID | – | – |
| 7b | 0.6 | 1 | IN | – | – |
| 3b | 0.7 | 1 | IN | – | – |
| Melanoma | |||||
| 1 | 2.0 | 3 | ID | PD | – |
| 2 | 1.1 | 2 | ID | PD | – |
| 3 | 0.6 | 3 | ID (1) IN (2) | SD | 4 |
| 4 | 1.8 | 3 | IN | PD | – |
| 6 | 1.0 | 3 | ID | SD | 4 |
| 8 | 2.3 | 3 | IN | SD | 8 |
| 9 | 1.7 | 10 | ID | SD | 17+ |
| 10 | 1.0 | 9 | ID | SD | 12 |
| 11 | 2.5 | 6 | ID (1) IN (5) | SD | 7 |
| 12 | 1.0 | 8 | ID (6) IN (2) | SD | 11 |
| 13 | 3.0 | 4 | IN | SD | 6 |
| 5 | 0.6 | 1 | ID | – | – |
| 7 | 2.6 | 1 | ID | – | – |
aDuration of response counted from protocol inclusion
bPatient who received only one dose of the vaccine and therefore was not evaluated at 3 months